AgeX Therapeutics (NYSEMKT:AGE) inks
a non-binding letter of intent with ImStem Biotechnology to obtain from
AgeX, a non-exclusive license to use its embryonic stem cell line ESI
053 to derive ImStem’s investigational MSC product IMS001 for
development in COVID-19 as well as acute respiratory distress syndrome
(ARDS) due to other causes.
Financial terms and other provisions of agreement are yet to be finalized.
https://seekingalpha.com/news/3579547-agex-therapeuticsplus-12-on-esi-053-deal-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.